

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington\_D.C. 20231

Attorney Docket No.: 16994-012710US

TOWNSEND and TOWNSEND and CREW LLP

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

Not Assigned

Johannes B.M.M. van Bree

Art Unit:

1712

Application No.: 09/454,711

Filed: December 6, 1999

REQUEST FOR CORRECTED FILING RECEIPT

For: TREATMENT OF POMPE'S DISEASE

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center

Washington, D.C. 20231

Sir:

ENT OF POMPE'S DISEASE

nissioner for Patents

Patent Examination
ce Center
C. 20231

Attached is a copy of the official Filing Receipt received from the Patent and Trademark
are noted application for which issuence of a corrected filing receipt is respectfully. Office in the above-noted application for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that one Applicant's City of Residence was mispelled and should read as follows:

## Saturnushof

The correction is not due to any error by applicant and no fee is due.

Respectfully submitted,

Joe Liebeschuetz Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (650) 326-2400 Fax: (650) 326-2422

JOL:slb PA 3072802 v1





# **Patent and Trademark Office**

Address: ASSISTANT SECRETARY AND COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

	APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
•	09/454,711	12/06/1999	1712	1864	16994-012710	4	34	5

20350 TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADERO CENTER **EIGHTH FLOOR** SAN FRANCISCO, CA 94111

Date Mailed: 04/10/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an rror is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "N tice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate an ther Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

JOHANNES B. M. M. VAN BREE, NIEUW-VENNEP, NETHERLANDS; EDNA H. G. VENNEKER, SAURNUSHOF, NETHERLANDS; DAVID P. MEEKER, CONCORD, MA;

SATURNUSHOF

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/111,291 12/07/1998

F reign Applications

If Required, Foreign Filing License Granted 01/06/2000

**Title** 

TREATMENT OF POMPE'S DISEASE

**Preliminary Class** 

525

Data entry by : BATES, DIANA

Team: OIPE

BECEINED 10116: 04/10/2000

 $T_{ij}$  (1974) and the finithman man finithman finithman finithman finithman finithman finithman finithman  $T_{ij}$ 





## LICENSE FOR FOREIGN FILING UNDER Title 35, United Stat s Cod , S ction 184 tle 37, Code of Federal Regulations, 5.11 & 5.15

**GRANTED** 

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, DC 20231









# UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER 09/454,711	12/06/1999 RULE _	<b>CLASS</b> 525	GROUP ART U 1712	D	ATTORNEY OCKET NO. 6994-012710							
APPLICANTS  JOHANNES B. M. M. VAN BREE, NIEUW-VENNEP, NETHERLANDS; EDNA H. G. VENNEKER, SATURNUSHOF, NETHERLANDS; DAVID P. MEEKER, CONCORD, MA;  ** CONTINUING DATA **********************************												
** FOREIGN APPLICATIONS ************************************												
Foreign Priority claimed												
ADDRESS  20350												
TITLE TREATMENT OF POMPE'S DISEASE												
RECEIVED No	ES: Authority has been g to charge/c for following	UNT   1.16   1.17   time )   1.18   1.18   1.18	All Fees  1.16 Fees (Filing)  1.17 Fees (Processing Ext. of time)  1.18 Fees (Issue)  Other  Credit									

4